Deep knowledge on
small-molecule drugs and
the 100,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

How are People Using DrugPatentWatch?

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: loteprednol etabonate; tobramycin

« Back to Dashboard
Loteprednol etabonate; tobramycin is the generic ingredient in one branded drug marketed by Bausch And Lomb and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are nine drug master file entries for loteprednol etabonate; tobramycin. One supplier is listed for this compound.

Summary for Generic Name: loteprednol etabonate; tobramycin

Tradenames:1
Patents:0
Applicants:1
NDAs:1
Drug Master File Entries: see list9
Suppliers / Packaging: see list3

Pharmacology for Ingredient: loteprednol etabonate; tobramycin

Clinical Trials for: loteprednol etabonate; tobramycin

Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis
Status: Completed Condition: Conjunctivitis

A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin
Status: Completed Condition: Ocular Hypertension

Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis
Status: Completed Condition: Conjunctivitis; Keratitis; Blepharitis

Pediatric Zylet Safety and Efficacy Study
Status: Completed Condition: Chalazion; Hordeolum

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis
Status: Active, not recruiting Condition: Meibomian Gland Dysfunction; Posterior Blepharitis

Zylet vs TobraDex in Blepharokeratoconjunctivitis
Status: Completed Condition: Blepharokeratoconjunctivitis

Ocular Tolerance and Intraocular Pressure (IOP) Effects of Zylet Versus Tobradex
Status: Completed Condition: Inflammation

Intraocular Pressure With Loteprednol and Dexamethasone
Status: Completed Condition: Glaucoma, Open-Angle; Ocular Hypertension

Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation
Status: Completed Condition: Healthy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 2004RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: loteprednol etabonate; tobramycin

These historical archives are available as an add-on to one-year subscriptions

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 20044,996,335*PED<disabled>
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 20045,540,930*PED<disabled>
Bausch And Lomb
ZYLET
loteprednol etabonate; tobramycin
SUSPENSION/DROPS;OPHTHALMIC050804-001Dec 14, 20045,747,061*PED<disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2016 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc